CSE: MEND | OTC: MNNDF | FRA: 8TV
Investor Presentation
Board & Advisors
Press Releases
December 6 - Nurosene Chief Science Officer Presents at Leading Drug Development Forum
December 1 - Nurosene Business Update
October 31 - Nurosene Health Inc. Announces Closing of Private Placement
October 14 - Nurosene Health Inc. Announces Closing Private Placement
August 24 - Nurosene Appoints Neurosurgeon Dr. Douglas James Cook as Chief Medical Officer
August 23 - Nurosene Appoints New Advisory Board Member Dhananja Jayalath
July 19 - Nurosene Announces Appointment of New CFO
July 14 - Nurosene Appoints Seasoned Executive Josh Spiegel as President of Netramark
June 8 - Nurosene Health Inc. Announces Closing of Private Placement
June 8 - Nurosene's Chief Scientific Officer to Present at World Orphan Drug Congress USA 2022
May 19 - Nurosene's Chief Scientific Officer Publishes Paper on AI and Placebo Response
Corporate Directory
Nurosene
[Head Office]
1655 Dupont St. #Suite 101
Toronto, ON M6P 3S9
investors@nurosene.com
Fasken Martineau DuMoulin LLP
[Legal]
2400 - 333 Bay St.
Toronto, ON M5H 2T6
416.366.8381
MNP LLP
[Auditors]
111 Richmond St. W Suite 300
Toronto, ON M5H 2G4
416.596.1711
Odyssey Trust
[Transfer Agent]
United Kingdom Building 323
409 Granville Street
Vancouver, BC V6C 1T2
1.833.392.7716